SOUTH SAN FRANCISCO, Calif. — September 30, 2026
Genentech announced new real-world results from the VOYAGER study evaluating Vabysmo (faricimab-svoa) in wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). The data, presented at the 2026 EURETINA Annual Meeting in Vienna, showed improvements in vision and retinal anatomy across previously untreated and previously treated eyes, with no new safety signals. VOYAGER includes more than 5,000 patients across 28 countries and regions, making it the largest prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical settings.
Vabysmo Demonstrates Vision and Anatomical Improvements
The VOYAGER results showed improvements in visual acuity and central subfield thickness across multiple retinal conditions. In wet AMD after 12 months, previously untreated eyes gained an average of 4.6 ETDRS letters and experienced a 110.5 µm reduction in central subfield thickness, while previously treated eyes maintained vision with a 26.1 µm reduction in thickness. In DME, previously untreated eyes gained 8.2 letters with a 127.8 µm reduction in thickness, while previously treated eyes gained 2.7 letters with a 71.3 µm reduction.
VOYAGER Shows Improvements Across RVO Subtypes
Vabysmo also produced visual and anatomical improvements in retinal vein occlusion. After six months of treatment, patients with branch RVO who had not received prior treatment gained an average of 10.0 ETDRS letters and experienced a 171.3 µm reduction in central subfield thickness. Previously treated branch RVO eyes gained 2.0 letters with a 59.0 µm reduction. In central/hemi-RVO, previously untreated eyes gained 16.6 letters and experienced a 287.4 µm reduction in thickness, while previously treated eyes gained 3.9 letters with a 63.4 µm reduction. Subretinal and intraretinal fluid also declined across the study cohorts..
Advertisement
Genentech Highlights Vabysmo’s Real-World Safety and Durability
The VOYAGER findings showed a Vabysmo safety profile generally consistent with previous Phase III studies. Across the wet AMD and DME cohorts, fewer Vabysmo injections were administered during months 7–12 than during months 1–6, suggesting that treatment intervals could be extended over time. The study uses AI and deep-learning algorithms to evaluate SD-OCT imaging collected during routine clinical practice, providing additional analysis of retinal fluid and anatomical changes. Vabysmo is a bispecific antibody that targets angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) and is approved for wet AMD, DME and, in multiple markets, macular edema following RVO.
Source: Genentech, press release
